Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Feb;39(2):542–544. doi: 10.1128/aac.39.2.542

Susceptibilities of fluoroquinolone-resistant strains of Campylobacter jejuni to 11 oral antimicrobial agents.

J L Gomez-Garces 1, R Cogollos 1, J L Alos 1
PMCID: PMC162576  PMID: 7726529

Abstract

The resistance of Campylobacter jejuni strains to the fluoroquinolones is increasingly frequent, and in our area it reaches nearly 50%. We studied the susceptibilities of 60 of these strains to 11 oral antibiotics. All strains except one were susceptible to the macrolides tested, with azithromycin being the most active agent tested. Of the rest of the antibiotics studied, amoxicillin-clavulanic acid, clindamycin, and fosfomycin displayed good in vitro activities. Knowledge of the susceptibilities of these microorganisms to a varied group of oral agents is necessary in view of the appearance of multiresistant strains, such as those included in our series.

Full Text

The Full Text of this article is available as a PDF (160.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrews J. M., Baquero F., Beltran J. M., Canton E., Crokaert F., Gobernado M., Gomez-Ius R., Loza E., Navarro M., Olay T. International collaborative study on standardization of bacterial sensitivity to fosfomycin. J Antimicrob Chemother. 1983 Oct;12(4):357–361. doi: 10.1093/jac/12.4.357. [DOI] [PubMed] [Google Scholar]
  2. Eghafona N. O., Ahmad A. A., Odama L. E., Onuora C., Gosham L. T., Emejuaiwe S. O., Woghiren E. I. The levels of measles antibodies in Nigerian children aged 0-12 months and its relationship with maternal parity. Epidemiol Infect. 1987 Oct;99(2):547–550. doi: 10.1017/s0950268800068047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Endtz H. P., Ruijs G. J., van Klingeren B., Jansen W. H., van der Reyden T., Mouton R. P. Quinolone resistance in campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine. J Antimicrob Chemother. 1991 Feb;27(2):199–208. doi: 10.1093/jac/27.2.199. [DOI] [PubMed] [Google Scholar]
  4. Figueroa G., Troncoso M., Galeno H., Soto V., Toledo M. S. Biotypes, serogroups and antibiotic susceptibility of Campylobacter jejuni and Campylobacter coli in Chile. J Infect. 1990 Mar;20(2):123–127. doi: 10.1016/0163-4453(90)93314-i. [DOI] [PubMed] [Google Scholar]
  5. Goossens H., De Mol P., Coignau H., Levy J., Grados O., Ghysels G., Innocent H., Butzler J. P. Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogens. Antimicrob Agents Chemother. 1985 Mar;27(3):388–392. doi: 10.1128/aac.27.3.388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gootz T. D., Martin B. A. Characterization of high-level quinolone resistance in Campylobacter jejuni. Antimicrob Agents Chemother. 1991 May;35(5):840–845. doi: 10.1128/aac.35.5.840. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gómez J. L., Alos J. I., Amor E., Cogollos R., Pérez A. Bacteriemia por Campylobacter jejuni resistente a ácido nalidíxico y fluoroquinolonas. Enferm Infecc Microbiol Clin. 1993 Jan;11(1):58–59. [PubMed] [Google Scholar]
  8. McNulty C. A. The treatment of campylobacter infections in man. J Antimicrob Chemother. 1987 Mar;19(3):281–284. doi: 10.1093/jac/19.3.281. [DOI] [PubMed] [Google Scholar]
  9. Page W. J., Huyer G., Huyer M., Worobec E. A. Characterization of the porins of Campylobacter jejuni and Campylobacter coli and implications for antibiotic susceptibility. Antimicrob Agents Chemother. 1989 Mar;33(3):297–303. doi: 10.1128/aac.33.3.297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Rautelin H., Renkonen O. V., Kosunen T. U. Emergence of fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli in subjects from Finland. Antimicrob Agents Chemother. 1991 Oct;35(10):2065–2069. doi: 10.1128/aac.35.10.2065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Reina J., Borrell N., Serra A. Emergence of resistance to erythromycin and fluoroquinolones in thermotolerant Campylobacter strains isolated from feces 1987-1991. Eur J Clin Microbiol Infect Dis. 1992 Dec;11(12):1163–1166. doi: 10.1007/BF01961137. [DOI] [PubMed] [Google Scholar]
  12. Sjögren E., Kaijser B., Werner M. Antimicrobial susceptibilities of Campylobacter jejuni and Campylobacter coli isolated in Sweden: a 10-year follow-up report. Antimicrob Agents Chemother. 1992 Dec;36(12):2847–2849. doi: 10.1128/aac.36.12.2847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Taylor D. E., Courvalin P. Mechanisms of antibiotic resistance in Campylobacter species. Antimicrob Agents Chemother. 1988 Aug;32(8):1107–1112. doi: 10.1128/aac.32.8.1107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Van der Auwera P., Scorneaux B. In vitro susceptibility of Campylobacter jejuni to 27 antimicrobial agents and various combinations of beta-lactams with clavulanic acid or sulbactam. Antimicrob Agents Chemother. 1985 Jul;28(1):37–40. doi: 10.1128/aac.28.1.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Williams M. D., Schorling J. B., Barrett L. J., Dudley S. M., Orgel I., Koch W. C., Shields D. S., Thorson S. M., Lohr J. A., Guerrant R. L. Early treatment of Campylobacter jejuni enteritis. Antimicrob Agents Chemother. 1989 Feb;33(2):248–250. doi: 10.1128/aac.33.2.248. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES